

MEDIA RELEASE

For immediate release

February 3rd, 2022



NEMIS Technologies Ltd. closes CHF 7.75 million Series A Funding Round

Investment will enable the Swiss Biotech Startup to further scale up its production, boost product development and pursue its ambitious internationalization strategy to meet increasing global demand

Dübendorf, Zurich - NEMIS Technologies Ltd., amongst the Top 15 Swiss Biotech Startups of 2021, announces the closing of a CHF 7.75 million Series A financing round with the participation of both institutional and private investors. NEMIS specializes in fast, easy-to-use, affordable and reliable on-site pathogen detection solutions. The company will use the investment to scale up its production, accelerate its ongoing international expansion, boost product development and relocate to new laboratory and office facilities in Au, ZH, Switzerland.

Arnaud Muller, CEO NEMIS, stated:

"Following the great care and dedication of our team over the past year to rapidly industrialize and scale our production, the capital raised will enable us to accelerate our expansion in Europe and overseas. We also have the means to accelerate the development of additional diagnostic test kits and methods to further improve our offering, strengthen our organization in a targeted manner and to reach profitable growth. This would not be possible without the great trust from our partners and investors, for which we are very grateful."

Roger Meier, the Chairman of the Board, added:

"In just three years, NEMIS has transformed itself from an interesting start-up into a very dynamic and promising growth company with a value proposition that serves a rapidly growing need in an almost optimal way. We are very pleased that we were able to inspire different types of investors - from the extraordinary successful company leader and entrepreneur to the international highly specialized, renown Foodtech fund, who will accompany us on our further journey. With gratitude and confidence, we look forward to creating great benefit for our stakeholders."

About health challenges from food borne pathogens

Food borne pathogens like *Listeria Monocytogenes*, *Salmonella*, *E. Coli* and others can be found everywhere and are spreading rapidly throughout global food and supply chains. They make hundreds of thousands of consumers sick every year, and can even be fatal. Contamination by microorganisms also causes huge amounts of food waste. Lastly, food manufacturers and distributors are increasingly confronted with product recalls, which not only cause immense financial costs, but also major reputational damage to the companies concerned. By the means of rapid detection and elimination, NEMIS is aiming at significantly reducing the health and cost burden of such pathogens to society.

MEDIA RELEASE

For immediate release

February 3rd, 2022



About NEMIS Technologies Ltd

NEMIS Technologies Ltd. [www.nemistech.com] founded in January 2018 by an experienced team of entrepreneurs, scientists and diagnostics, medical and food business professionals. Its patented core technology opens up a near-endless application space for the detection, identification, or monitoring of bacteria, parasites, viruses, or fungi. Unlike most other technologies, the company's kits can be used anywhere by anyone, empowering food producers to take back control. By meeting several stringent requirements simultaneously, the young company is now on the verge of setting a new transformative industry standard. The power of mass testing closes the current environment control gaps and enables permanent process control in the food chain and allows for preventative elimination of contaminated sites to massively improve product safety.

Media Contact – NEMIS Technologies Ltd

Franziska Gartenmann

Growth Manager

+41 76 395 87 03

franzisca.gartenmann@nemistech.com